Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 28;38(34):4042–4054. doi: 10.1200/JCO.20.00948

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Landmark Kaplan-Meier analyses. (A) Progression-free survival (PFS) from end of combination therapy (EOCT) in both study arms based on minimal residual disease (MRD) status at EOCT. (B) PFS from end of treatment (EOT) in patients in the venetoclax plus rituximab (VenR) arm who completed 2 years of venetoclax, based on MRD status at EOT (excludes two patients who completed venetoclax but experienced disease progression before MRD measurement). (C) PFS from EOCT in the VenR arm based on MRD status at EOCT and involvement of lymph nodes. BR, bendamustine plus rituximab; CR, complete response; CRi, complete response with incomplete marrow recovery; nPR, nodular partial response; PR, partial response; uMRD, undetectable minimal residual disease.